These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37088447)

  • 1. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.
    Gabrielle PH; Delyfer MN; Glacet-Bernard A; Conart JB; Uzzan J; Kodjikian L; Arndt C; Tadayoni R; Soudry-Faure A; Creuzot Garcher CP
    Ophthalmology; 2023 Sep; 130(9):947-957. PubMed ID: 37088447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
    Jackson TL; Bunce C; Desai R; Hillenkamp J; Lee CN; Lois N; Peto T; Reeves BC; Steel DH; Edwards RT; van Meurs JC; Wafa H; Wang Y
    Trials; 2022 Jan; 23(1):99. PubMed ID: 35101110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Displacement of Submacular Hemorrhage Using Subretinal Cocktail Injection versus Pneumatic Displacement: A Real-World Comparative Study.
    Szeto SKH; Tsang CW; Mohamed S; Lee GKY; Lok JKH; Hui VWK; Tsang KK; Chen LJ; Brelen M; Lai TYY
    Ophthalmologica; 2024; 247(2):118-132. PubMed ID: 38408445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
    Bardak H; Bardak Y; Erçalık Y; Erdem B; Arslan G; Timlioglu S
    Eur J Ophthalmol; 2018 May; 28(3):306-310. PubMed ID: 29148027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration.
    Sniatecki JJ; Ho-Yen G; Clarke B; Barbara R; Lash S; Papathomas T; Antonakis S; Gupta B
    Eur J Ophthalmol; 2021 Mar; 31(2):643-648. PubMed ID: 31813290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fundus Autofluorescence Patterns in Subretinal Hemorrhages Associated with Neovascular Age-Related Macular Degeneration.
    Nawrocka ZA; Nawrocki J
    Ophthalmologica; 2024; 247(1):58-64. PubMed ID: 38113868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
    Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
    Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Submacular combination treatment for management of acute, massive submacular hemorrhage in age-related macular degeneration.
    Shah SP; Hubschman JP; Gonzales CR; Schwartz SD
    Ophthalmic Surg Lasers Imaging; 2009; 40(3):308-15. PubMed ID: 19485299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.
    Tranos P; Tsiropoulos GN; Koronis S; Vakalis A; Asteriadis S; Stavrakas P
    Int Ophthalmol; 2021 Dec; 41(12):4037-4046. PubMed ID: 34331185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naïve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study.
    Iglicki M; Khoury M; Melamud JI; Donato L; Barak A; Quispe DJ; Zur D; Loewenstein A
    Eye (Lond); 2023 Jun; 37(8):1659-1664. PubMed ID: 36038720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations and Outcomes of Patients with Submacular Hemorrhage Secondary to Age-related Macular Degeneration in the IVAN Trial.
    Mehta A; Steel DH; Muldrew A; Peto T; Reeves BC; Evans R; Chakravarthy U;
    Am J Ophthalmol; 2022 Apr; 236():89-98. PubMed ID: 34626573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
    Fassbender JM; Sherman MP; Barr CC; Schaal S
    Retina; 2016 Oct; 36(10):1860-5. PubMed ID: 26945238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subretinal Coapplication of Tissue Plasminogen Activator and Bevacizumab with Concurrent Pneumatic Displacement for Submacular Hemorrhages Secondary to Neovascular Age-Related Macular Degeneration.
    Avcı R; Mavi Yıldız A; Çınar E; Yılmaz S; Küçükerdönmez C; Akalp FD; Avcı E
    Turk J Ophthalmol; 2021 Feb; 51(1):38-44. PubMed ID: 33631914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pars plana vitrectomy and subretinal tissue plasminogen activator for large exudative submacular hemorrhage: a case series.
    Patikulsila D; Winaikosol P; Choovuthayakorn J; Watanachai N; Chaikitmongkol V; Kunavisarut P
    BMC Ophthalmol; 2022 Oct; 22(1):411. PubMed ID: 36303103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases.
    González-López JJ; McGowan G; Chapman E; Yorston D
    Eye (Lond); 2016 Jul; 30(7):929-35. PubMed ID: 27055681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey.
    Inoue N; Kato A; Araki T; Kimura T; Kinoshita T; Okamoto F; Murakami T; Mitamura Y; Sakamoto T; Miki A; Takamura Y; Matsubara H; Tsujinaka H; Gomi F; Yasukawa T
    PLoS One; 2022; 17(7):e0271447. PubMed ID: 35862313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. "The Submarine Study".
    Iglicki M; Khoury M; Donato L; Quispe DJ; Negri HP; Melamud JI
    Eye (Lond); 2024 Feb; 38(2):292-296. PubMed ID: 37537388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.